RYBREVANT® plus LAZCLUZE™ shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
J&J는 EGFRxMET 이중항체 ‘아미반타맙 (제품명 리브리반트)’와 유한양행이 개발해 J&J에 라이선스아웃한 3세대 EGFR TKI ‘레이저티닙 (제품명 라즈클루즈)’가 타크리소 대비 환자의 OS를 통계적으로, 임상적으로 유의미하게 개선했다고 밝힘. Johnson & Johnson has announced that its chemotherapy-free combination of Rybrevant® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib) has demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to […]
European Commission approves RYBREVANT® in combination with LAZCLUZE® for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
유럽연합 집행위원회는 EGFR 변이 진행성 비소세포폐암 환자의 1차 치료제로 J&J의 RYBREVANT®(amivantamab)와 유한양행이 개발해 J&J에 라이선스아웃한LAZCLUZE®(lazertinib)와의 병용 요법을 승인함. The European Commission has approved the combination of RYBREVANT® (amivantamab) and LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or L858R substitution mutations. This […]
RYBREVANT® plus LAZCLUZE™ by Johnson & Johnson got approved by the U.S. FDA as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. LAZCLUZE™ is anti-cancer drug developed by Yuhan Corporation licensed out to Janssen Biotech in 2018.
Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved […]
Business Development Manager Position Available
We’re #hiring. Know anyone who might be interested? Please feel free to share this information with others who may be interested.
Yuhan USA team attended NEBS 2024 32nd Annual Conference
Yuhan USA team attended NEBS 2024 32nd Annual Conference on May 18th at the Harvad Medical School. Yuhan is a proud sponsor of NEBS and it’s always great to connect with such a talented group of scientists. Special congratulations to Dr. Won-Seok Lee for receiving NEBS-Yuhan award! His work on “Cells with intranuclear Huntingtin aggregates have long (>150) somatic CAG-repeat […]
Yuhan USA to participate at 2024 BIO International Convention in June
Yuhan USA to participate at 2024 BIO International Convention in June Yuhan USA, a subsidiary of Yuhan Corporation, will be participating in 2024 BIO International Convention on June 3-6 (San Diego, CA). Yuhan USA is looking for potential therapeutic assets with validated proof-of-concept data for in-licensing. The company’s R&D focus areas are Oncology (targeted therapy, […]
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients (biospectator.com)
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients YH35324 is an Fc fusion protein of the IgE series, ‘IgE Trap’, which is a form that fuses the extracellular domain of the IgE receptor (FcεR1) with a hybrid Fc. Its main mechanism of action is […]
‘Amivantamab’ and ‘Lazertinib’ Combination Treatment Shows Extended PFS as First-line of Therapy in NSCLC
Yuhan Corporation’s 3rd generation EGFR TKI, ‘Lazertinib’, has taken another step towards its global blockbuster aspirations.This achievement comes as a result of successful outcomes in the clinical trial named ‘MARIPOSA,’ in which Janssen evaluated the anti-cancer drug ‘Amivantamab’ in combination with ‘Lazertinib’ compared to AstraZeneca’s ‘Osimertinib’. According to industry reports on October 2nd, Janssen, a […]
Yuhan and Cyrus Therapeutics signed an agreement for Joint Research on Anti-Cancer Target Therapeutics
Yuhan announced that it has signed an MOU with Cyrus Therapeutics to develop a small molecule anti-cancer target therapy. Cyrus Therapeutics is a Korean biotechnology company with small molecule therapeutics and targeted proteolysis (TPD) technology that degrades protein and removes cancer cells. Through the agreement, the two companies plan to cooperate in the fields of […]
Yuhan Corporation Announces Free Supply of Its New Lung Cancer Drug “Lazertinib” Until Covered by Insurance through Expanded Access Program (EAP) in South Korea
Yuhan Corporation, a leading pharmaceutical company, has announced that it will provide its newly developed drug, “Lazertinib,” as a first-line treatment for free until it is covered by health insurance in South Korea. This initiative is in line with the company’s commitment to giving back to society, a value that was cherished by its late […]